Abstract: The research and development of new antibiotics to deal with drug-resistant bacterial infection has become the main strategy of World Health Organization. Under the incentive of new drug R&D policies, the research and development of new antibiotics has attracted the attention of new drug research institutions. During the recent 10 years, quite a few innovative antibacterial drugs have been launched to the market or under development at different stages. In this review, the main drugs in the global market for the treatment of drug-resistant bacterial infections are introduced, including new β-lactamase inhibitor, cephalosporins, glycopeptides, tetracyclines, oxazolidinones, etc., with particular attention to their related pharmacology, clinical research, and safety, aiming to provide reference for the related research and clinical application.